Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.

The pharmaceutical firm is growing its presence across three states, creating 3,000 jobs.

Pharmaceutical giant Eli Lilly announced Wednesday that it plans to invest roughly $27 billion in United States manufacturing more than doubling its investment over the past five years. The company said this will be the largest pharmaceutical manufacturing investment in United States history.

The pharmaceutical company expects the expansion will create thousands of jobs.

Indianapolis-based pharmaceutical giant Eli Lilly and Co. announced plans Wednesday to add four new manufacturing sites in a roughly $27 billion investment expected to create 3,000 jobs and nearly 10,000 construction positions during the buildout.

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 billion in four new manufacturing sites in the United States. But the company made it clear that those plans hinge on tax cuts.